306 citations,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
2 citations,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
15 citations,
August 2016 in “Current Urology Reports” Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.
77 citations,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
50 citations,
July 2021 in “Nature Communications” The drug enzalutamide may reduce the ability of the virus causing COVID-19 to enter lung cells.
23 citations,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
17 citations,
January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
1 citations,
January 2024 in “Curēus” Clinicians should use social and prescription data to track trends in performance-enhancing drug use.
October 2023 in “Frontiers in endocrinology” Androgens and androgen receptors are important for metabolic health, affecting how the body uses glucose and fats through mitochondrial function.
90 citations,
May 2019 in “Drugs” Long-term use of azole antifungals can cause hair loss, hormonal imbalances, and severe skin reactions.
56 citations,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.